Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

被引：0

作者：

Dimitrios Pectasides

Vasilios Karavasilis

George Papaxoinis

Georgia Gourgioti

Thomas Makatsoris

Georgia Raptou

Eleni Vrettou

Joseph Sgouros

Epaminontas Samantas

George Basdanis

Pavlos Papakostas

Dimitrios Bafaloukos

Vassiliki Kotoula

Haralambos P. Kalofonos

Chrisoula D. Scopa

George Pentheroudakis

George Fountzilas

机构：

[1] “Hippokration” Hospital,Oncology Section, Second Department of Internal Medicine

[2] Aristotle University of Thessaloniki School of Medicine,Department of Medical Oncology, “Papageorgiou” Hospital

[3] Section of Biostatistics,Division of Oncology, Department of Medicine

[4] Hellenic Cooperative Oncology Group,Department of Pathology

[5] Data Office,Third Department of Medical Oncology

[6] University Hospital,First Propaedeutic Department of Surgery, “AHEPA” Hospital

[7] University of Patras Medical School,Department of Medical Oncology

[8] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology

[9] “Agii Anargiri” Cancer Hospital,Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research

[10] Aristotle University of Thessaloniki School of Medicine,Department of Pathology

[11] “Hippokration” Hospital,Department of Medical Oncology

[12] “Metropolitan” Hospital,undefined

[13] Aristotle University of Thessaloniki School of Medicine,undefined

[14] University Hospital,undefined

[15] University of Patras Medical School,undefined

[16] Ioannina University Hospital,undefined

来源：

BMC Cancer | / 15卷

关键词：

Colorectal cancer; Adjuvant chemotherapy; Modified FOLFOX6; Capecitabine; Oxaliplatin; Prognosis; KRAS; Microsatellite instability;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
Pectasides, Dimitrios
Karavasilis, Vasilios
Papaxoinis, George
Gourgioti, Georgia
Makatsoris, Thomas
Raptou, Georgia
Vrettou, Eleni
Sgouros, Joseph
Samantas, Epaminontas
Basdanis, George
Papakostas, Pavlos
Bafaloukos, Dimitrios
Kotoula, Vassiliki
Kalofonos, Haralambos P.
Scopa, Chrisoula D.
Pentheroudakis, George
Fountzilas, George
BMC CANCER, 2015, 15
[2] Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study
Osawa, Hiroshi
Handa, Naoko
Minakata, Kunihiko
ONCOLOGY RESEARCH, 2015, 22 (5-6) : 325 - 331
[3] Adjuvant 5-Fluorouracil/leucovorin, capecitabine, and oxaliplatin-related regimens for stage II/III colon cancer patients 66 years or older
Jones, Emily
Duan, Zhigang
Nguyen, Thinh T.
Giordano, Sharon H.
Zhao, Hui
CANCER MEDICINE, 2023, 12 (03): : 2389 - 2406
[4] POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs . SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial
Su, Liyu
Zhao, Shen
Yin, Yi
Huang, Feng
Zhu, Jinfeng
Chen, Luchuan
Lin, Rongbo
FRONTIERS IN MEDICINE, 2022, 9
[5] Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)
Kim, Jeong Eun
Hong, Yong Sang
Kim, Hwa Jung
Kim, Kyu-pyo
Kim, Sun Young
Lim, Seok-Byung
Park, In Ja
Kim, Chan Wook
Yoon, Yong Sik
Yu, Chang Sik
Kim, Jin Cheon
Kim, Ji Hun
Kim, Tae Won
ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (05) : 1289 - 1294
[6] Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)
Jeong Eun Kim
Yong Sang Hong
Hwa Jung Kim
Kyu-pyo Kim
Sun Young Kim
Seok-Byung Lim
In Ja Park
Chan Wook Kim
Yong Sik Yoon
Chang Sik Yu
Jin Cheon Kim
Ji Hun Kim
Tae Won Kim
Annals of Surgical Oncology, 2017, 24 : 1289 - 1294
[7] High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy
Yang, I-Ping
Miao, Zhi-Feng
Huang, Ching-Wen
Tsai, Hsiang-Lin
Yeh, Yung-Sung
Su, Wei-Chih
Chang, Tsung-Kun
Chang, Se-fen
Wang, Jaw-Yuan
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
[8] Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
Christos Emmanouilides
Georgia Sfakiotaki
Nikolaos Androulakis
Kostas Kalbakis
Charalambos Christophylakis
Antonia Kalykaki
Lambros Vamvakas
Athanasios Kotsakis
Sofia Agelaki
Eleni Diamandidou
Nikolaos Touroutoglou
Adam Chatzidakis
Vassilis Georgoulias
Dimitris Mavroudis
John Souglakos
BMC Cancer, 7
[9] Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
A Sobrero
G Frassineti
A Falcone
L Dogliotti
R Rosso
F D Costanzo
P Bruzzi
British Journal of Cancer, 2005, 92 : 24 - 29
[10] Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
Sobrero, A
Frassineti, G
Falcone, A
Dogliotti, L
Rosso, R
Costanzo, FD
Bruzzi, P
BRITISH JOURNAL OF CANCER, 2005, 92 (01) : 24 - 29

← 1 2 3 4 5 →